Stannous fluoride Dentifrice

Phase 3

HHALEON

Stannous fluoride Dentifrice is one of 3 therapeutic programs targeting Diabetes, Type 2. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetes, Type 2Enrolling by invitation

Diabetes, Type 2Phase 3

Enrolling by invitation

Competition

Competitive Landscape

2 competitors in Diabetes, Type 2

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Approved

1 2

Glucophage

EMD Serono

Approved

1 3

Stannous fluoride Dentifrice

HHALEON

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetes, Type 21 trial

Clinical Study to Evaluate the Efficacy of an Oral Health Behavioral Intervention on Medical and Dental Claims in People With Diabetes

Enrolling by invitation·CColgate Palmolive·Approved·NCT07619729·10,000 enrolled

Dentin Hypersensitivity1 trial

Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

Completed·HHALEON·Phase 3·NCT07215767·688 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Stannous fluoride Dentifrice. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Stannous fluoride Dentifrice. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — HALEON company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: HHALEON

Stannous fluoride Dentifrice

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Diabetes, Type 21 trial

Dentin Hypersensitivity1 trial

References

Drug Info

Quick Facts

Related News